Join Us: Weill Cornell Medicine Kidney Cancer Patient Education Symposium

We are excited to announce that Weill Cornell Medicine’s first Kidney Cancer Patient Education Symposium will take place on Saturday, May 18, 2019, from 9AM – 2PM. 

Join fellow patients, and connect with leading medical experts as our own Dr. Ana Molina hosts discussions surrounding the most exciting updates in kidney cancer research and care. Here’s a sneak peek at what we have in store:

Updates inKidneyCancer Research & TreatmentKC Event
Maria Carlo, MD – Genetics
Memorial Sloan Kettering Cancer Center
 
Tim McClure, MD
– Interventional Radiology
Weill Cornell Medicine
Ana Molina, MD – Medical Oncology
Weill Cornell Medicine
Himanshu Nagar, MD – Radiation Oncology
Weill Cornell Medicine
Douglas Scherr, MD – Surgery
Weill Cornell Medicine

Coping with Kidney Cancer
Speaker TBA

The Power of Clinical Trials
Dena Battle
President, KCCure

Advancements in Immunotherapy
Charles Drake, MD, PhD 
Genitourinary Oncology, Columbia University Irving Medical Center

The Symposium will be hosted on the third floor of Weill Cornell Medicine’s Belfer Research Building (413 E. 69th Street | New York, NY 10065). Breakfast and networking will begin at 8AM. Lunch will also be provided.

The event is free and open to all patients and loved ones impacted by kidney cancer. RSVP is required. Reserve your seat today: http://bit.ly/kidneycancersymposium19

 

Premier MRI-Guided Radiotherapy Technology Enables Real-Time Tumor Tracking

Radiotherapy is a core element of prostate cancer treatment, yielding cures in men with localized disease. The goal of prostate cancer radiotherapy is to deliver high doses of radiation to the prostate gland while avoiding the surrounding bladder and rectum, thus preventing unwanted urinary and gastrointestinal side effects and preserving patient quality of life.

Radiotherapy guided by magnetic resonance imaging (MRI) allows clinicians to visualize a tumor as well as its neighboring organs in order to most accurately deliver treatment to the target region.

Weill Cornell Medicine and NewYork-Presbyterian Hospital (WCM/NYP) are proud to be the first – and only – medical institution in the northeast to offer patients the most premier MRI-guided radiotherapy technology available: the MRIdian Linear Accelerator, by ViewRay. The MRIdian Linac’s unique ability to track a patient’s tumor in real time during treatment makes it by far the most advanced modality of delivering radiation.

Real-time visualization is significant due to the constant flux of internal human anatomy, including changes in respiration, digestion and bladder fill that can influence the position of the prostate within the body. Even a minor shift of the tumor target during treatment can have major implications related to potential side effects of radiation. If the bladder or rectum displace the prostate during treatment, the MRIdian Linac machine will cease delivery of radiation and not resume until the prostate moves back in bounds of the target region. Whereas other modalities track small fiducial markers implanted in the prostate, this machine allows clinicians to see and track the tumor itself.

In addition, WCM/NYP is the only center in the area to offer combined use of MRI-guided radiotherapy with the rectal SpaceOAR, a hydrogel barrier that is temporarily placed between the prostate and rectum to shield the rectum from radiation and further reduce potential side effects.

Watch the video below to learn more about this state-of-the-art technology from WCM/NYP radiation oncologist Dr. Himanshu Nagar.

 

Targeting Prostate-Specific Membrane Antigen (PSMA)

Our team is at the forefront of utilizing prostate-specific membrane antigen (PSMA)-targeted therapies in the treatment of prostate cancer.

PSMA is a protein on the surface of prostate cancer cells that enables a targeted approach to locate and image or treat these cells wherever they are in the body, even those that have escaped (metastasized) to other organs. We are able to target PSMA using different types of drugs, including small molecules and antibodies.

Targeting Prostate-Specific Membrane Antigen (PSMA)

Learn more about how we use antibodies and small molecules to target PSMA.

For examples of our work in action, browse open prostate cancer clinical trials at Weill Cornell Medicine and NewYork-Presbyterian.